30 closest matches · ranked by relevance
Ampulla of Vater Adenocarcinoma · Small Intestinal Adenocarcinoma · Stage III Ampulla of Vater Cancer AJCC v8
Primary: Number of Participants With Progression-free Survival (PFS) at Six Months — 68 percentage of participants
Rectal Carcinoma · Rectosigmoid Carcinoma
Primary: Bowel Function — 30.8; 29.5 MSK-BFI score on a scale (range 18-90)
Small Intestine Adenocarcinoma · Recurrent Small Intestine Cancer
Primary: Confirmed Tumor Response Rate (Proportion of Participants With Complete Response) — .38 proportion of patients
Small Bowel Cancers · Colorectal Cancers
Primary: Objective Response Rate (ORR) for Triple Therapy — 0; 0 Proportion of participants
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Colorectal Cancer
Primary: Percent of Patients Receiving GI Consult for FOBT+ Results — 39; 47; 64; 51 percent patients receiving GI consult
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Colorectal Neoplasm · Colorectal Cancer
Primary: Number of Patients With Adverse Events — 5; 0 Participants
Colorectal Cancer With Non Resectable Hepatic Metastasis
Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
Head and Neck Cancer · Synbiotics · Nutrition Therapy
Primary: Serum DAO Enzyme Concentration — 3; 2.5 ng/mL
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Colorectal Cancer
Primary: Colorectal Cancer Screening Participation, Defined as Completion of a Guaiac or Immunochemical Stool Occult Blood Test, Colonoscopy, Sigmoidoscopy, or Barium Enem…
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Colorectal Cancer
Primary: Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0) — 7; 2; 40; 42 percentage of participants
Colorectal Carcinoma
Primary: Pharmacological Effect on Cyclic Guanosine Monophosphate (cGMP) Levels for Dolcanatide Arm Versus (vs.) Placebo, as Measured by the Differences in Mean cGMP Levels After…
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
Colorectal Cancer
Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients